Heparin Sodium Wockhardt Uk

Heparin Sodium Wockhardt Uk is an injectable anticoagulant that contains the active ingredient heparin sodium. It is supplied as a sterile intravenous solution intended for use under medical supervision. The product conforms to European Union standards and is classified as a prescription‑only medication. By potentiating antithrombin III, it helps inhibit thrombin and factor Xa, reducing the risk of pathological clot formation in patients at risk of thrombosis.

Heparin Sodium Wockhardt Uk is used in clinical settings to prevent and treat thromboembolic conditions where rapid anticoagulation is required.

- Prevention and treatment of deep vein thrombosis (DVT) in hospitalized or immobile patients. - Prevention and treatment of pulmonary embolism (PE) following surgery or trauma. - Anticoagulation during cardiac, vascular, or cardiopulmonary bypass procedures. - Maintenance of circuit patency in extracorporeal dialysis or hemofiltration systems. - Prophylaxis of clot formation in patients with atrial fibrillation undergoing invasive procedures. - Adjunctive anticoagulation in patients receiving thrombolytic therapy for acute myocardial infarction.

Heparin Sodium Wockhardt Uk may be associated with a range of adverse effects, which are generally categorized by frequency and clinical significance.

Common: - Minor bleeding at the injection site or from mucous membranes. - Small bruising (ecchymosis) in areas of venipuncture. - Transient elevation of liver enzymes. - Nausea or mild gastrointestinal discomfort. - Transient low platelet count without clinical significance. - Mild headache or dizziness.

Serious: - Major hemorrhage, including intracranial or gastrointestinal bleeding. - Heparin‑induced thrombocytopenia (HIT) with a rapid drop in platelet count. - Allergic reactions such as rash, itching, or anaphylaxis. - Spinal or epidural hematoma when used in neuraxial procedures. - Acute adrenal insufficiency due to bilateral adrenal hemorrhage.

When prescribing Heparin Sodium Wockhardt Uk, clinicians should evaluate patient‑specific factors and monitor for conditions that increase bleeding risk.

- Assess baseline coagulation parameters (aPTT, PT/INR) before initiation. - Review history of heparin‑induced thrombocytopenia or other heparin allergies. - Use caution in patients with active gastrointestinal ulcers, recent surgery, or intracranial lesions. - Adjust dose or avoid use in severe renal or hepatic impairment. - Monitor platelet counts regularly to detect HIT early. - Avoid concurrent use with other anticoagulants or antiplatelet agents unless medically justified. - Consider pregnancy status, as safety data are limited.

Heparin Sodium Wockhardt Uk can interact with several medications, influencing anticoagulant effect or bleeding risk.

Avoid: - Concurrent use with other parenteral anticoagulants such as low‑molecular‑weight heparin or direct thrombin inhibitors. - Combination with potent antiplatelet agents (e.g., clopidogrel, ticagrelor) without close monitoring. - Co‑administration with fibrinolytic drugs (e.g., alteplase, streptokinase) due to heightened hemorrhagic potential.

Use with caution: - Non‑steroidal anti‑inflammatory drugs (NSAIDs) and aspirin may increase minor bleeding; monitor gastrointestinal tolerance. - Certain antibiotics (e.g., vancomycin, cefazolin) can alter platelet function; observe for signs of HIT. - Herbal supplements such as ginkgo biloba, garlic, or high‑dose vitamin E may potentiate anticoagulation; assess patient use.